Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00887926
Other study ID # 13959
Secondary ID CP17-0801I5C-IE-
Status Terminated
Phase Phase 1
First received
Last updated
Start date June 2009
Est. completion date August 2010

Study information

Verified date December 2022
Source Eli Lilly and Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.


Description:

The purpose of this study is to define the maximum tolerated dose (MTD) and the pharmacokinetic (PK) profile of the anti-FMS-like tyrosine kinase 3 (FLT3) monoclonal antibody IMC-EB10, administered weekly in participant with acute lymphoblastic leukemia (AML) who have failed to achieve complete remission to a standard induction regimen, relapsed after response to previous antileukemia therapy, or are not eligible for potentially curative or approved salvage options.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date August 2010
Est. primary completion date August 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The participant has acute myeloid leukemia in the bone marrow or blood that has relapsed with or without a prior complete remission 2. The participant is not regarded to be a candidate for a potentially curative, higher priority treatment for acute myeloid leukemia 3. The participant has resolution of all clinically significant toxic effects of any prior antitumor therapy and any other study-specific clinical or laboratory parameter specified in the entry criteria 4. The participant has not had major surgery, an open biopsy, a significant injury, and/or prior antitumor therapy (except antileukemia therapy) within 21 days prior to the first infusion of IMC-EB10 5. The participant has an Eastern Cooperative Oncology Group (ECOG)performance status of 0, 1, or 2 at study entry. 6. The participant is age 18 years or older 7. The participant has a life expectancy of >3 months 8. The participant has adequate liver and kidney function, as defined in the entry criteria 9. The participant is using an effective contraception (per the institutional standard), if procreative potential exists 10. The participant is able to give written informed consent 11. The participant is willing and able to comply with study procedures, scheduled visits, and treatment plans Exclusion Criteria: 1. The participant has had prior allogenic or autologous stem cell transplant within <3 months of the first infusion of IMC-EB10 2. The participant has had an organ transplant (nonhematologic) within 3 years of study entry 3. The participant has active central nervous system leukemia 4. The participant has extramedullary disease without peripheral/and or bone marrow involvement 5. The participant is disease-free from a previous or concurrent malignancy for a period = 1 year. A participant who has basal cell carcinoma or carcinoma in situ of the cervix will not be excluded from the study 6. The participant is currently receiving antileukemia therapy. Concurrent treatment with hydroxyurea is permitted 7. The participant has uncontrolled intercurrent illness as specified in the study entry criteria 8. The participant is receiving chronic steroid or other immunosuppressive medications. Occasional use of steroid-containing medications for, for example (e.g.), asthma exacerbation or for skin lesions, is permitted 9. The participant is receiving full-dose heparin (including low molecular weight heparin) or warfarin. [The participant is permitted to use low-dose warfarin to maintain patency of preexisting, permanent, indwelling intravenous (I.V.) catheters.] 10. The participant is pregnant (confirmed by urine or serum pregnancy test) or breast feeding 11. The participant has received treatment with monoclonal antibodies within 6 weeks prior to first infusion of IMC-EB10 12. The participant has a history of clinically significant allergic reactions to monoclonal antibodies or other therapeutic proteins

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
IMC-EB10
Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle

Locations

Country Name City State
United States ImClone Investigational Site Columbus Ohio
United States ImClone Investigational Site Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerate Dose (MTD) of IMC-EB10 MTD is defined as the dose preceding the dose level at which 2 participants experienced a dose limiting toxicity (DLT) during Cycle 1. DLT is defined using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE v 3.0): (1) any Grade 3 or 4 toxicity that is clearly not attributable to leukemia [for example (e.g.) a type of end-organ failure that is infrequently encountered in acute myeloid leukemia (AML)] and is possibly, probably, or definitely attributable to IMC-EB10 in the judgment of the investigator; and (2) any Grade 3 or 4 toxicity that is clearly not attributable to a co-medication (e.g., prolonged neutropenia that is not attributable to hydroxyurea). Cycle 1 (28-day cycle)
Secondary Pharmacokinetic (PK): Maximum Concentration (Cmax) Cycle 1 Week 1: predose, immediately after infusion, and 1.5, 2, 4, 8, 24, 96, and 168 h after infusion ends, and Cycle 1 Week 3: predose, immediately after infusion, and 1.5, 2, 4, 8, 24, 48, 96,168, 240 and 336 h after infusion ends (28-day cycles)
Secondary PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Measurable Concentration [AUC(0-last)] Cycle 1 Week 1: predose, immediately after infusion, and at 1.5, 2, 4, 8, 24, 96 and 168 h after infusion ends (28-day cycle)
Secondary PK: Area Under the Concentration Time Curve During the Dosing Interval (AUCtau) Where Tau is 168 Hours Cycle 1 Week 3: predose, immediately after infusion and at 1.5, 2, 4, 8, 24, 48, 96,168, 240 and 336 h after infusion ends (28-day cycle)
Secondary Number of Participants With Adverse Events (AEs) (Safety Profile of IMC-EB10) Clinically significant events were defined as serious adverse events (SAEs) and other non-serious AEs regardless of causality. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module 8 weeks and 30-day post-treatment follow-up
Secondary Number of Participants With Anti-IMC-EB10 Antibodies A participant is considered positive for antibodies against IMC-EB10 if their blood sample exhibited a post-treatment antibody level that exceeds the positive upper cut point determined from the anti-IMC-EB10 level in healthy untreated individuals. A participant was considered to have an anti-IMC-EB10 response if there are 2 consecutive positive samples or if the final sample tested is positive. Cycle 1, Weeks 1 and 3 and Cycle 2, Week 1: predose (28-day cycles)
Secondary Number of Participants With Antileukemic Complete Response (CR) or Partial Response (PR) Assessment of antileukemic response was based on hematologic response criteria. PR defined as >1000/microliter (µL) neutrophils and =100000/µL platelets in peripheral blood; a decrease of =50% in the pretreatment percentage of blasts to 5% to 25% in the bone marrow aspirate or a value of =5% blasts if Auer rods are present. Cytogenetic CR defined as normal cytogenetic findings. Molecular CR defined as negative findings for minimal residual disease by automated quantitative Reverse-Transcription-Polymerase Chain Reaction (RT-PCR) and multidimensional flow cytometry. Morphologic CR with incomplete blood count recovery defined as =5% blasts (containing no Auer rods) in a bone marrow aspirate with spicules; neutrophil count < 1000/µL or platelets <100000/mL in peripheral blood or no extramedullary leukemia present. 4 weeks
Secondary Number of Participants With Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 3 (FLT3) Response FLT3 response to IMC-EB10 is defined as wild type, internal tandem duplications (ITD) mutations and other mutations. Week 4 and Week 8
See also
  Status Clinical Trial Phase
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Terminated NCT00543972 - Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia Phase 1
Completed NCT00521664 - A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups Phase 3
Completed NCT05363488 - Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
Completed NCT01380756 - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia Phase 1
Recruiting NCT05031897 - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant Phase 2
Terminated NCT00126893 - Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia Phase 1
Completed NCT03613727 - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Phase 2
Active, not recruiting NCT04714372 - FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Phase 1
Recruiting NCT06235801 - A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT02763475 - NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents Phase 2
Terminated NCT01643603 - Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Phase 1
Completed NCT00497991 - Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia Phase 1
Withdrawn NCT05309018 - Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML
Not yet recruiting NCT05787951 - Frequency and Risk Factors of Acute Myeloid Leukemia
Completed NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Early Phase 1
Completed NCT02719821 - Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation N/A
Active, not recruiting NCT00111345 - Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Phase 2/Phase 3
Completed NCT00114764 - Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML) Phase 2
Recruiting NCT05871008 - Integrated Actionable Aging Assessment for Cancer Patients Pilot N/A